Selective Aldosterone Synthase Inhibitors via Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aldosterone synthase inhibitors have undesired side effects such as inhibiting the production of cortisol, testosterone, and estradiol, and lack selectivity in inhibiting aldosterone production, necessitating the development of new compounds that can selectively target aldosterone synthase while minimizing interference with other steroid hormone production.
Innovation Solution
Development of compounds of the formula 4-[(4R)-6,6-dimethyl-4,5-dihydro-1H-cyclopenta[c]pyrazol-4-yl]benzonitrile or its pharmaceutically acceptable salts, which act as selective aldosterone synthase inhibitors, potentially used in combination with other therapeutic agents for treating chronic kidney disease, diabetic nephropathy, congestive heart failure, and hypertension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current aldosterone synthase inhibitors are used, then aldosterone production is inhibited, but cortisol, testosterone, and estradiol production are also inhibited causing side effects
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: the pyrazole core provides selective binding to aldosterone synthase, while specific substituents (R1, R2, R3, R4, R5, R6) are optimized to interact with the aldosterone synthase active site without interfering with other steroidogenic enzymes. This localized functional differentiation enables selective inhibition of aldosterone production while preserving cortisol, testosterone, and estradiol synthesis.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including the pyrazole ring structure, substituent types (halogens, alkyl groups, aryl groups), and their positions on the core structure. These parameter modifications tune the compound's selectivity profile, optimizing binding affinity for aldosterone synthase while reducing off-target effects on other steroidogenic enzymes.
2Reliability
If current aldosterone synthase inhibitors are used, then aldosterone production is inhibited, but selectivity for aldosterone over other steroids is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core pyrazole structure that provides baseline selectivity, and multiple substituent positions (R1-R6) that can be independently optimized. This segmented approach allows each portion of the molecule to contribute specifically to aldosterone synthase binding, enhancing overall selectivity through cumulative effects of individual segments.
Solution Approach 2:
The patent employs asymmetry by introducing chiral centers and asymmetric substituent patterns on the pyrazole core. The non-symmetric arrangement of substituents creates a three-dimensional binding interface that is highly specific for aldosterone synthase, exploiting the asymmetric nature of the enzyme's active site to achieve superior selectivity over symmetric or less specific inhibitor structures.
Data Source
Figure 1
Figure 2
AI summary
The present invention provides aldosterone synthase inhibitors of the formula (I): intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.